S 9156
Latest Information Update: 04 Apr 2008
At a glance
- Originator Sonus Pharmaceuticals; State University of New York
- Class
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypovolaemia
Most Recent Events
- 04 Apr 2008 Discontinued - Preclinical for Hypovolaemia in USA (unspecified route)
- 02 Nov 2005 No development reported - Preclinical for Hypovolaemia in USA (unspecified route)
- 13 Jan 2003 This compound is still in active development